Remove 2026 Remove Patients Remove Treatment
article thumbnail

ACA Council on Chiropractic Pediatrics launches 2025-2026 hybrid program cohort

Chiropractic Economics

The American Chiropractic Association (ACA) Council on Chiropractic Pediatrics has launched its 2025-2026 hybrid program, a 300-hour course of study that prepares doctors of chiropractic for the pediatrics diplomate certification exam. To learn more, visit acatoday.org.

article thumbnail

Laser focus boosting athletic performance with low-level laser therapy

Chiropractic Economics

This is a fundamental change in the clinical toolbox that will allow healthcare providers to deliver a higher level of service and enhanced clinical outcomes to their patient populations. We can’t wait to see what he does in 2026. as quickly as possible. during the 2012 Summer Olympics in London in 2012.

Ligaments 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Osteochondritis Dissecans of the Knee

Orthopedic Principles

Courtesy: Prof Michael Hantes, ESSKA 1st Vice President Ivory Orange Modern Meet Our Team Instagram Post – 1 Lecture Topic: Osteochondritis Dissecans of the Knee Aim: Define the treatment algorithm for this disease. Treatment depends on: Age, lesion size, symptoms, and patient expectations. Avoidance of high-impact sports.

X-ray 52
article thumbnail

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoSpineNews

The designation covers the use of the therapeutic medical device to treat patients who continue to experience knee pain or impairment following a meniscus surgery, which impacts approximately 250,000 Americans annually. ” OrthoPreserve hopes to launch their Pilot clinical trial in 2026, while aiming for potential FDA approval by 2029.

article thumbnail

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

OrthoSpineNews

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo.,

Spine 52